NCT02075125

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Dong-A University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Detailed description

Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of this study is to compare the antiplatelet efficacy and safety using laboratory platelet function tests and clinical outcomes in patients with STEMI treated with either prasugrel or ticagrelor.

Conditions

• ST-Segment Elevation Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Prasugrel 60 mg	Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
DRUG	Ticagrelor 180 mg	Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.

Timeline

• Start date: 2014-01-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2014-03-03
• Last updated: 2017-08-18
• Results posted: 2016-02-01

Locations

1 site across 1 country: South Korea